Source: Scripps Research Institute From: sciencedaily.com Scientists from the Florida campus of The Scripps Research Institute (TSRI) have created a new class of antibody-drug conjugates (ADCs), using a versatile “double decker” technology that ties antibodies and a drug together to produce highly potent pharmaceuticals for cancer therapy. The new ADC technology advances a class of pharmaceuticals that use antibodies to …
-
-
Psyching Ourselves Out in a Positive Way as a Breast Cancer Survivor
-
My Home is My Haven for This Breast Cancer Survivor
-
As a Breast Cancer Survivor, There is Nothing Like Doing What You Love
-
The True Meaning of Easter
-
Peace for a Breast Cancer Survivor
